Pulmonary hypertension primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pulmonary hypertension}} | {{Pulmonary hypertension}} | ||
{{CMG}} | |||
==Overview== | |||
Patients who are at elevated risk for developing pulmonary arterial hypertension (PAH) must be monitored for the occurrence of symptoms of PAH. Patients at risk for PAH include subjects with [[systemic sclerosis]] or with genetic predisposition.<ref name="pmid24937180">{{cite journal| author=Taichman DB, Ornelas J, Chung L, Klinger J, Lewis S, Mandel J et al.| title=Pharmacological Therapy for Pulmonary Arterial Hypertension in Adults: CHEST Guideline. | journal=Chest | year= 2014 | volume= | issue= | pages= | pmid=24937180 | doi=10.1378/chest.14-0793 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24937180 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 19:02, 27 August 2014
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension primary prevention On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension primary prevention |
|
Risk calculators and risk factors for Pulmonary hypertension primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Patients who are at elevated risk for developing pulmonary arterial hypertension (PAH) must be monitored for the occurrence of symptoms of PAH. Patients at risk for PAH include subjects with systemic sclerosis or with genetic predisposition.[1]
References
- ↑ Taichman DB, Ornelas J, Chung L, Klinger J, Lewis S, Mandel J; et al. (2014). "Pharmacological Therapy for Pulmonary Arterial Hypertension in Adults: CHEST Guideline". Chest. doi:10.1378/chest.14-0793. PMID 24937180.